|
1
|
Misek DE and Kim EH: Protein biomarkers
for the early detection of breast cancer. Int J Proteomics.
2011:3435822011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu FJ, Hua XF and Wang WJ: A new
bioinformatics insight into human cancer-associated proteins. Oncol
Rep. 27:1932–1936. 2012.PubMed/NCBI
|
|
3
|
Kamel D, Brady B, Tabchy A, Mills GB and
Hennessy B: Proteomic classification of breast cancer. Curr Drug
Targets. 13:1495–1509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goncalves A and Bertucci F: Clinical
application of proteomics in breast cancer: state of the art and
perspectives. Med Princ Pract. 20:4–18. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hondermarck H, Tastet C, El
Yazidi-Belkoura I, Toillon RA and Le Bourhis X: Proteomics of
breast cancer: the quest for markers and therapeutic targets. J
Proteome Res. 7:1403–1411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kadowaki M, Sangai T, Nagashima T,
Sakakibara M, Yoshitomi H, Takano S, Sogawa K, Umemura H, Fushimi
K, Nakatani Y, Nomura F and Miyazaki M: Identification of
vitronectin as a novel serum marker for early breast cancer
detection using a new proteomic approach. J Cancer Res Clin Oncol.
137:1105–1115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Issaq HJ, Waybright TJ and Veenstra TD:
Cancer biomarker discovery: Opportunities and pitfalls in
analytical methods. Electrophoresis. 32:967–975. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sawyers CL: The cancer biomarker problem.
Nature. 452:548–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hua XF, Wang XB and Liu FJ: Functional
analysis of human cancer-associated genes and their association
with the testes and epididymis. Oncol Lett. 6:811–816.
2013.PubMed/NCBI
|
|
10
|
Ordóñez NG: Application of
immunohistochemistry in the diagnosis of epithelioid mesothelioma:
a review and update. Hum Pathol. 44:1–19. 2013.PubMed/NCBI
|
|
11
|
Fritzsche FR, Dahl E, Pahl S, Burkhardt M,
Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C,
Winzer KJ, Diete M and Kristiansen G: Prognostic relevance of AGR2
expression in breast cancer. Clin Cancer Res. 12:1728–1734. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan M and Yu D: Molecular mechanisms of
erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol.
608:119–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Goldstein RH, Scepansky EM and
Rosenblatt M: Inhibition of rho-associated kinase signaling
prevents breast cancer metastasis to human bone. Cancer Res.
69:8742–8751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soga T: Cancer metabolism: key players in
metabolic reprogramming. Cancer Sci. 104:275–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Basten SG and Giles RH: Functional aspects
of primary cilia in signaling, cell cycle and tumorigenesis. Cilia.
2:62013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palmer TD, Ashby WJ, Lewis JD and Zijlstra
A: Targeting tumor cell motility to prevent metastasis. Adv Drug
Deliv Rev. 63:568–581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Behrens J: The role of cell adhesion
molecules in cancer invasion and metastasis. Breast Cancer Res
Treat. 24:175–184. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA
and Chae HZ: Overexpression of peroxiredoxin in human breast
cancer. Anticancer Res. 21:2085–2090. 2001.PubMed/NCBI
|
|
19
|
Karihtala P, Mäntyniemi A, Kang SW,
Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin
Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
|
|
20
|
Bae JY, Ahn SJ, Han W and Noh DY:
Peroxiredoxin I and II inhibit H2O2-induced
cell death in MCF-7 cell lines. J Cell Biochem. 101:1038–1045.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di
GH, Jin W, Ou ZL, Shen ZZ and Shao ZM: Identification of the
functional role of peroxiredoxin 6 in the progression of breast
cancer. Breast Cancer Res. 9:R762007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nomura T and Katunuma N: Involvement of
cathepsins in the invasion, metastasis and proliferation of cancer
cells. J Med Invest. 52:1–9. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Decock J, Obermajer N, Vozelj S, Hendrickx
W, Paridaens R and Kos J: Cathepsin B, cathepsin H, cathepsin X and
cystatin C in sera of patients with early-stage and inflammatory
breast cancer. Int J Biol Markers. 23:161–168. 2008.PubMed/NCBI
|
|
24
|
Peck AR, Witkiewicz AK, Liu C, Klimowicz
AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH,
Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm
DL, Magliocco AM, Hyslop T and Rui H: Low levels of Stat5a protein
in breast cancer are associated with tumor progression and
unfavorable clinical outcomes. Breast Cancer Res. 14:R1302012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu-Jun L, Shao-Hua J and Xiao-Fang S:
Differential proteomic analysis of pathway biomarkers in human
breast cancer by integrated bioinformatics. Oncol Lett.
4:1097–1103. 2012.PubMed/NCBI
|
|
26
|
Arcinas A, Yen TY, Kebebew E and Macher
BA: Cell surface and secreted protein profiles of human thyroid
cancer cell lines reveal distinct glycoprotein patterns. J Proteome
Res. 8:3958–3968. 2009. View Article : Google Scholar
|
|
27
|
Esseghir S, Kennedy A, Seedhar P, Nerurkar
A, Poulsom R, Reis-Filho JS and Isacke CM: Identification of NTN4,
TRA1, and STC2 as prognostic markers in breast cancer in a screen
for signal sequence encoding proteins. Clin Cancer Res.
13:3164–3173. 2007. View Article : Google Scholar : PubMed/NCBI
|
